Novel nanotechnology approaches to diagnosis and therapy of ovarian cancer

Gynecologic Oncology

Volumn 120, Issue 3, 2011, Pages 393-403

  Kim, Paul S ^a   Djazayeri, Shabdis ^a   Zeineldin, Reema ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Detection; Diagnosis; Imaging; Nanomedicine; Nanotechnology; Ovarian cancer; Screening; Theranostics; Therapy

Indexed keywords

ALBUMIN; ANTIBODY; APOLIPOPROTEIN A1; BETA 2 MICROGLOBULIN; CA 125 ANTIGEN; CADMIUM SELENIDE; CARBOPLATIN; CISPLATIN; COLLOIDAL GOLD; CONTRAST MEDIUM; DENDRIMER; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLATE RECEPTOR; FOLLITROPIN RECEPTOR; GONADORELIN RECEPTOR; IMMUNOGLOBULIN; IRON OXIDE; LIGAND; MACROGOL; MAGNETIC NANOPARTICLE; NANOCARRIER; NANOCRYSTAL; PACLITAXEL; PREALBUMIN; QUANTUM DOT; TRANSFERRIN; UNINDEXED DRUG; VASCULOTROPIN; ZINC SULFIDE;

ARTICLE; CANCER SCREENING; CANCER THERAPY; CYTOREDUCTIVE SURGERY; DRUG DELIVERY SYSTEM; GENE TARGETING; HUMAN; IMAGING; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR WEIGHT; NANOBIOTECHNOLOGY; NANOMEDICINE; NANOTECHNOLOGY; NEAR INFRARED SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PELVIC EXAMINATION; PRIORITY JOURNAL; PROTEOMICS; TRANSVAGINAL ECHOGRAPHY;

FEMALE; GENE THERAPY; HUMANS; NANOTECHNOLOGY; NITRIC OXIDE; OVARIAN NEOPLASMS; PHOTOTHERAPY;

EID: 79951578633     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.11.029     Document Type: Article

References (190)

1. V. Jayde, K. White, and P. Blomfield Symptoms and diagnostic delay in ovarian cancer: a summary of the literature Contemp Nurse 34 2009 55 65
2. P.M. Das, and R.C. Bast Jr. Early detection of ovarian cancer Biomark Med 2 2008 291 303
3. T.I. Williams, K.L. Toups, D.A. Saggese, K.R. Kalli, W.A. Cliby, and D.C. Muddiman Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers J Proteome Res 6 2007 2936 2962 (Pubitemid 47310180)
4. M. Markman Pharmaceutical management of ovarian cancer: current status Drugs 68 2008 771 789 (Pubitemid 351550530)
5. Jemal A., Siegel R., Xu J., and Ward E. Cancer statistics, 2010 CA Cancer J Clin 2010
6. N. Auersperg, A.S. Wong, K.C. Choi, S.K. Kang, and P.C. Leung Ovarian surface epithelium: biology, endocrinology, and pathology Endocr Rev 22 2001 255 288 (Pubitemid 32458162)
7. R. Scully, R. Young, and P. Clement Tumors of the ovary, maldeveloped gonads, allopian tube, and broad ligament 1998 Armed Forces Institute of Pathlogy Washington DC
8. L.G. Hudson, R. Zeineldin, and M.S. Stack Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression Clin Exp Metastasis 25 2008 643 655
9. Lengyel E. Ovarian cancer development and metastasis Am J Pathol 2010
10. K. Shield, M.L. Ackland, N. Ahmed, and G.E. Rice Multicellular spheroids in ovarian cancer metastases: biology and pathology Gynecol Oncol 113 2009 143 148
11. A.P. Heintz, F. Odicino, P. Maisonneuve, M.A. Quinn, J.L. Benedet, and W.T. Creasman Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer Int J Gynaecol Obstet 95 Suppl 1 2006 S161 S192
12. T.I. Williams, K.L. Toups, D.A. Saggese, K.R. Kalli, W.A. Cliby, and D.C. Muddiman Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers J Proteome Res 6 2007 2936 2962 (Pubitemid 47310180)
13. O. Metzger-Filho, C. Moulin, and V. D'Hondt First-line systemic treatment of ovarian cancer: a critical review of available evidence and expectations for future directions Curr Opin Oncol 22 2010 513 520
14. J. Liu, and U.A. Matulonis New advances in ovarian cancer Oncology 24 2010 721 728 (Williston Park)
15. A.G. Zeimet, D. Reimer, A.C. Radl, A. Reinthaller, C. Schauer, and E. Petru Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer Anticancer Res 29 2009 2803 2808
16. M. Markman, and J.L. Walker Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment J Clin Oncol 24 2006 988 994 (Pubitemid 46638854)
17. I.V. Filippovich, N.I. Sorokina, N. Robillard, and J.F. Chatal Radiation-induced apoptosis in human ovarian carcinoma cells growing as a monolayer and as multicell spheroids Int J Cancer 72 1997 851 859 (Pubitemid 27431530)
18. S. Makhija, D.D. Taylor, R.K. Gibb, and C. Gercel-Taylor Taxol-induced bcl-2 phosphorylation in ovarian cancer cell monolayer and spheroids Int J Oncol 14 1999 515 521
19. M. Bardies, P. Thedrez, J.F. Gestin, B.M. Marcille, D. Guerreau, and A. Faivre-Chauvet Use of multi-cell spheroids of ovarian carcinoma as an intraperitoneal radio-immunotherapy model: uptake, retention kinetics and dosimetric evaluation Int J Cancer 50 1992 984 991
20. M.Y. Fong, and S.S. Kakar The role of cancer stem cells and the side population in epithelial ovarian cancer Histol Histopathol 25 2010 113 120
21. M.P. Ponnusamy, and S.K. Batra Ovarian cancer: emerging concept on cancer stem cells J Ovarian Res 1 2008 4
22. S.A. Bapat Human ovarian cancer stem cells Reproduction 140 2010 33 41
23. S. Zhang, C. Balch, M.W. Chan, H.C. Lai, D. Matei, and J.M. Schilder Identification and characterization of ovarian cancer-initiating cells from primary human tumors Cancer Res 68 2008 4311 4320
24. L. Hu, C. McArthur, and R.B. Jaffe Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant Br J Cancer 102 2010 1276 1283
25. L.E. van Vlerken, T.K. Vyas, and M.M. Amiji Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery Pharm Res 24 2007 1405 1414 (Pubitemid 46988224)
26. K. Cho, X. Wang, S. Nie, Z.G. Chen, and D.M. Shin Therapeutic nanoparticles for drug delivery in cancer Clin Cancer Res 14 2008 1310 1316 (Pubitemid 351413909)
27. J.R. Baker Jr. Dendrimer-based nanoparticles for cancer therapy Hematol Am Soc Hematol Educ Program 2009 708 719
28. M. Vallet-Regi Nanostructured mesoporous silica matrices in nanomedicine J Intern Med 267 2010 22 43
29. M. Prato, K. Kostarelos, and A. Bianco Functionalized carbon nanotubes in drug design and discovery Acc Chem Res 41 2008 60 68
30. Z. Liu, S. Tabakman, K. Welsher, and H. Dai Carbon nanotubes in biology and medicine: in vitro and in vivo detection, imaging and drug delivery Nano Res 2 2009 85 120
31. O. Veiseh, J.W. Gunn, and M. Zhang Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging Adv Drug Deliv Rev 62 2010 284 304
32. R. Arvizo, R. Bhattacharya, and P. Mukherjee Gold nanoparticles: opportunities and challenges in nanomedicine Expert Opin Drug Deliv 7 2010 753 763
33. S.S. Agasti, S. Rana, M.H. Park, C.K. Kim, C.C. You, and V.M. Rotello Nanoparticles for detection and diagnosis Adv Drug Deliv Rev 62 2010 316 328
34. A.P. Alivisatos, W. Gu, and C. Larabell Quantum dots as cellular probes Annu Rev Biomed Eng 7 2005 55 76 (Pubitemid 41170185)
35. D.J. Bharali, M. Khalil, M. Gurbuz, T.M. Simone, and S.A. Mousa Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers Int J Nanomedicine 4 2009 1 7
36. M. Longmire, P.L. Choyke, and H. Kobayashi Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats Nanomed 3 2008 703 717
37. A.M. Chen, M. Zhang, D. Wei, D. Stueber, O. Taratula, and T. Minko Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells Small 5 2009 2673 2677
38. L.L. Klein, K.R. Jonscher, M.J. Heerwagen, R.S. Gibbs, and J.L. McManaman Shotgun proteomic analysis of vaginal fluid from women in late pregnancy Reprod Sci 15 2008 263 273 (Pubitemid 351550936)
39. S. Dasari, L. Pereira, A.P. Reddy, J.E. Michaels, X. Lu, and T. Jacob Comprehensive proteomic analysis of human cervical-vaginal fluid J Proteome Res 6 2007 1258 1268 (Pubitemid 46724022)
40. M.K. Di Quinzio, K. Oliva, S.J. Holdsworth, M. Ayhan, S.P. Walker, and G.E. Rice Proteomic analysis and characterisation of human cervico-vaginal fluid proteins Aust N Z J Obstet Gynaecol 47 2007 9 15 (Pubitemid 46152463)
41. Fribourg A. Ovarian cancer test clears regulatory requirements for sale in Europe 2010
42. Publication on OvaCheck Question and Answer from Clinical Proteomics Program http://home.ccr.cancer.gov/ncifdaproteomics/ppatterns.asp
43. C. Kuk, V. Kulasingam, C.G. Gunawardana, C.R. Smith, I. Batruch, and E.P. Diamandis Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers Mol Cell Proteomics 8 2009 661 669
44. L. Gortzak-Uzan, A. Ignatchenko, Evangelou A.I., Agochiya M., Brown K.A., and St Onge P. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers J Proteome Res 7 2008 339 351 (Pubitemid 351171148)
45. R. Terracciano, L. Pasqua, F. Casadonte, S. Frasca, M. Preiano, and D. Falcone Derivatized mesoporous silica beads for MALDI-TOF MS profiling of human plasma and urine Bioconjug Chem 20 2009 913 923
46. E.P. Diamandis Peptidomics for cancer diagnosis: present and future J Proteome Res 5 2006 2079 2082 (Pubitemid 44330798)
47. Fredolini C., Meani F., Luchini A., Zhou W., Russo P., and Ross M. Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology AAPS J 2010 Published online.
48. F. Meani, S. Pecorelli, L. Liotta, and E.F. Petricoin Clinical application of proteomics in ovarian cancer prevention and treatment Mol Diagn Ther 13 2009 297 311
49. H.J. An, S. Miyamoto, K.S. Lancaster, C. Kirmiz, B. Li, and K.S. Lam Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer J Proteome Res 5 2006 1626 1635 (Pubitemid 44043097)
50. D.A. Barkauskas, H.J. An, S.R. Kronewitter, M.L. de Leoz, H.K. Chew, and de Vere White R.W. Detecting glycan cancer biomarkers in serum samples using MALDI FT-ICR mass spectrometry data Bioinformatics 25 2009 251 257
51. G.S. Leiserowitz, C. Lebrilla, S. Miyamoto, H.J. An, H. Duong, and C. Kirmiz Glycomics analysis of serum: a potential new biomarker for ovarian cancer? Int J Gynecol Cancer 18 2008 470 475 (Pubitemid 351668296)
52. B. Li, H.J. An, C. Kirmiz, C.B. Lebrilla, K.S. Lam, and S. Miyamoto Glycoproteomic analyses of ovarian cancer cell lines and sera from ovarian cancer patients show distinct glycosylation changes in individual proteins J Proteome Res 7 2008 3776 3788
53. B. Sun, J.A. Ranish, A.G. Utleg, J.T. White, X. Yan, and B. Lin Shotgun glycopeptide capture approach coupled with mass spectrometry for comprehensive glycoproteomics Mol Cell Proteomics 6 2007 141 149 (Pubitemid 46152699)
54. M. Di Michele, S. Marcone, L. Cicchillitti, Della Corte A., Ferlini C., and Scambia G. Glycoproteomics of paclitaxel resistance in human epithelial ovarian cancer cell lines: towards the identification of putative biomarkers J Proteomics 73 2010 879 898
55. R. Philip, S. Murthy, J. Krakover, G. Sinnathamby, J. Zerfass, and L. Keller Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer J Proteome Res 6 2007 2509 2517 (Pubitemid 47122348)
56. K.E. Resnick, H. Alder, J.P. Hagan, D.L. Richardson, C.M. Croce, and D.E. Cohn The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform Gynecol Oncol 112 2009 55 59
57. M.J. Lodes, M. Caraballo, D. Suciu, S. Munro, A. Kumar, and B. Anderson Detection of cancer with serum miRNAs on an oligonucleotide microarray PLoS ONE 4 2009 e6229
58. D.H. Geho, L.A. Liotta, E.F. Petricoin, W. Zhao, and R.P. Araujo The amplified peptidome: the new treasure chest of candidate biomarkers Curr Opin Chem Biol 10 2006 50 55 (Pubitemid 43202287)
59. R.S. Tirumalai, K.C. Chan, D.A. Prieto, H.J. Issaq, T.P. Conrads, and T.D. Veenstra Characterization of the low molecular weight human serum proteome Mol Cell Proteomics 2 2003 1096 1103
60. K. Merrell, K. Southwick, S.W. Graves, M.S. Esplin, N.E. Lewis, and C.D. Thulin Analysis of low-abundance, low-molecular-weight serum proteins using mass spectrometry J Biomol Tech 15 2004 238 248
61. M. Zhou, D.A. Lucas, K.C. Chan, H.J. Issaq, E.F. Petricoin III, and L.A. Liotta An investigation into the human serum "interactome" Electrophoresis 25 2004 1289 1298
62. M.S. Lowenthal, A.I. Mehta, K. Frogale, R.W. Bandle, R.P. Araujo, and B.L. Hood Analysis of albumin-associated peptides and proteins from ovarian cancer patients Clin Chem 51 2005 1933 1945 (Pubitemid 41368193)
63. M.F. Lopez, A. Mikulskis, S. Kuzdzal, E. Golenko, E.F. Petricoin III, and L.A. Liotta A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples Clin Chem 53 2007 1067 1074 (Pubitemid 46867523)
64. D.H. Geho, C.D. Jones, E.F. Petricoin, and L.A. Liotta Nanoparticles: potential biomarker harvesters Curr Opin Chem Biol 10 2006 56 61 (Pubitemid 43202288)
65. A. Luchini, C. Fredolini, B.H. Espina, F. Meani, A. Reeder, and S. Rucker Nanoparticle technology: addressing the fundamental roadblocks to protein biomarker discovery Curr Mol Med 10 2010 133 141
66. C. Longo, A. Patanarut, T. George, B. Bishop, W. Zhou, and C. Fredolini Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers PLoS ONE 4 2009 e4763
67. M. Gaspari, Ming-Cheng Cheng M., Terracciano R., Liu X., Nijdam A.J., and Vaccari L. Nanoporous surfaces as harvesting agents for mass spectrometric analysis of peptides in human plasma J Proteome Res 5 2006 1261 1266 (Pubitemid 43727806)
68. R. Terracciano, M. Gaspari, F. Testa, L. Pasqua, P. Tagliaferri, and M.M. Cheng Selective binding and enrichment for low-molecular weight biomarker molecules in human plasma after exposure to nanoporous silica particles Proteomics 6 2006 3243 3250 (Pubitemid 43886143)
69. M. Najam-ul-Haq, M. Rainer, Z. Szabo, R. Vallant, C.W. Huck, and G.K. Bonn Role of carbon nano-materials in the analysis of biological materials by laser desorption/ionization-mass spectrometry J Biochem Biophys Meth 70 2007 319 328 (Pubitemid 46329145)
70. S. Xu, Y. Li, H. Zou, J. Qiu, Z. Guo, and B. Guo Carbon nanotubes as assisted matrix for laser desorption/ionization time-of-flight mass spectrometry Anal Chem 75 2003 6191 6195 (Pubitemid 37420612)
71. C.H. Wang, J. Li, S.J. Yao, Y.L. Guo, and X.H. Xia High-sensitivity matrix-assisted laser desorption/ionization Fourier transform mass spectrometry analyses of small carbohydrates and amino acids using oxidized carbon nanotubes prepared by chemical vapor deposition as matrix Anal Chim Acta 604 2007 158 164 (Pubitemid 350046244)
72. J.V. Jokerst, A. Raamanathan, N. Christodoulides, P.N. Floriano, A.A. Pollard, and G.W. Simmons Nano-bio-chips for high performance multiplexed protein detection: determinations of cancer biomarkers in serum and saliva using quantum dot bioconjugate labels Biosens Bioelectron 24 2009 3622 3629
73. Y.C. Hung, H.A. Pan, S.M. Tai, and G.S. Huang A nanodevice for rapid modulation of proliferation, apoptosis, invasive ability, and cytoskeletal reorganization in cultured cells Lab Chip 10 2010 1189 1198
74. J. Kim, B.C. Kim, D. Lopez-Ferrer, K. Petritis, and R.D. Smith Nanobiocatalysis for protein digestion in proteomic analysis Proteomics 10 2010 687 699
75. K. Riehemann, S.W. Schneider, T.A. Luger, B. Godin, M. Ferrari, and H. Fuchs Nanomedicine-challenge and perspectives Angew Chem Int Ed 48 2009 872 897
76. Y.E. Choi, J.W. Kwak, and J.W. Park Nanotechnology for early cancer detection Sensors 10 2010 428 455
77. S. Dutta, F.Q. Wang, A.C. Fleischer, and D.A. Fishman New frontiers for ovarian cancer risk evaluation: proteomics and contrast-enhanced ultrasound AJR Am J Roentgenol 194 2010 349 354
78. Fleischer A.C., Lyshchik A., Jones Jr. H.W., Crispens M., Loveless M., and Andreotti R.F. Contrast-enhanced transvaginal sonography of benign versus malignant ovarian masses: preliminary findings J Ultrasound Med 27 2008 1011 1018 quiz 1019-21. (Pubitemid 351991174)
79. A.C. Fleischer, A. Lyshchik, H.W. Jones III, M.A. Crispens, R.F. Andreotti, and P.K. Williams Diagnostic parameters to differentiate benign from malignant ovarian masses with contrast-enhanced transvaginal sonography J Ultrasound Med 28 2009 1273 1280
80. A.C. Fleischer, A. Lyshchik, R.F. Andreotti, M. Hwang, H.W. Jones III, and D.A. Fishman Advances in sonographic detection of ovarian cancer: depiction of tumor neovascularity with microbubbles AJR Am J Roentgenol 194 2010 343 348
81. X. Qian, X.H. Peng, D.O. Ansari, Q. Yin-Goen, G.Z. Chen, and D.M. Shin In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags Nat Biotechnol 26 2008 83 90
82. Z.B. Li, W. Cai, and X. Chen Semiconductor quantum dots for in vivo imaging J Nanosci Nanotechnol 7 2007 2567 2581
83. H. Xu, C.A. Regino, Y. Koyama, Y. Hama, A.J. Gunn, and M. Bernardo Preparation and preliminary evaluation of a biotin-targeted, lectin-targeted dendrimer-based probe for dual-modality magnetic resonance and fluorescence imaging Bioconjug Chem 18 2007 1474 1482 (Pubitemid 47464054)
84. N. Kamaly, T. Kalber, M. Thanou, J.D. Bell, and A.D. Miller Folate receptor targeted bimodal liposomes for tumor magnetic resonance imaging Bioconjug Chem 20 2009 648 655
85. R. Zhang, C. Wu, L. Tong, B. Tang, and Q.H. Xu Multifunctional core-shell nanoparticles as highly efficient imaging and photosensitizing agents Langmuir 25 2009 10153 10158
86. M. Zeisser-Labouebe, F. Delie, R. Gurny, and N. Lange Benefits of nanoencapsulation for the hypercin-mediated photodetection of ovarian micrometastases Eur J Pharm Biopharm 71 2009 207 213
87. Z. Liu, X. Li, S.M. Tabakman, K. Jiang, S. Fan, and H. Dai Multiplexed multicolor Raman imaging of live cells with isotopically modified single walled carbon nanotubes J Am Chem Soc 130 2008 13540 13541
88. S. Keren, C. Zavaleta, Z. Cheng, A. de la Zerda, O. Gheysens, and S.S. Gambhir Noninvasive molecular imaging of small living subjects using Raman spectroscopy Proc Natl Acad Sci USA 105 2008 5844 5849 (Pubitemid 351758460)
89. R. Popovtzer, A. Agrawal, N.A. Kotov, A. Popovtzer, J. Balter, and T.E. Carey Targeted gold nanoparticles enable molecular CT imaging of cancer Nano Lett 8 2008 4593 4596
90. B. Kang, D. Yu, Y. Dai, S. Chang, D. Chen, and Y. Ding Cancer-cell targeting and photoacoustic therapy using carbon nanotubes as "bomb" agents Small 5 2009 1292 1301
91. N.W. Kam, M. O'Connell, J.A. Wisdom, and H. Dai Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction Proc Natl Acad Sci USA 102 2005 11600 11605 (Pubitemid 41170772)
92. C.J. Gannon, P. Cherukuri, B.I. Yakobson, L. Cognet, J.S. Kanzius, and C. Kittrell Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field Cancer 110 2007 2654 2665 (Pubitemid 350250334)
93. P. Cherukuri, E.S. Glazer, and S.A. Curley Targeted hyperthermia using metal nanoparticles Adv Drug Deliv Rev 62 2010 339 345
94. X. Hun, Z. Zhang, and L. Tiao Anti-Her-2 monoclonal antibody conjugated polymer fluorescent nanoparticles probe for ovarian cancer imaging Anal Chim Acta 625 2008 201 206
95. B.B. Nathwani, M. Jaffari, A.R. Juriani, A.B. Mathur, and K.E. Meissner Fabrication and characterization of silk-fibroin-coated quantum dots IEEE Trans Nanobioscience 8 2009 72 77
96. H.Z. Wang, H.Y. Wang, R.Q. Liang, and K.C. Ruan Detection of tumor marker CA125 in ovarian carcinoma using quantum dots Acta Biochim Biophys Sin 36 2004 681 686 (Shanghai)
97. T.A. Zdobnova, S.G. Dorofeev, P.N. Tananaev, V.P. Zlomanov, O.A. Stremovskiy, and E.N. Lebedenko Imaging of human ovarian cancer SKOV-3 cells by quantum dot bioconjugates Dokl Biochem Biophys 430 2009 41 44
98. J.A. Gubbels, N. Claussen, A.K. Kapur, J.P. Connor, and M.S. Patankar The detection, treatment, and biology of epithelial ovarian cancer J Ovarian Res 3 2010 8
99. M. Markman, K. Webster, K. Zanotti, G. Peterson, B. Kulp, and J. Belinson Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials Gynecol Oncol 93 2004 699 701 (Pubitemid 38766058)
100. R.F. Ozols Challenges for chemotherapy in ovarian cancer Ann Oncol 17 Suppl 5 2006 v181 v187
101. R. Zeineldin, C.Y. Muller, M.S. Stack, and L.G. Hudson Targeting the EGF receptor for ovarian cancer therapy J Oncol 2010 2010 414676
102. H. Maeda The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting Adv Enzyme Regul 41 2001 189 207
103. K. Greish Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines J Drug Target 15 2007 457 464 (Pubitemid 47209047)
104. Fang J., Nakamura H., and Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv Drug Deliv Rev 2010 Pulished online.
105. H. Maeda, G.Y. Bharate, and J. Daruwalla Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect Eur J Pharm Biopharm 71 2009 409 419
106. A.E. Green, and P.G. Rose Pegylated liposomal doxorubicin in ovarian cancer Int J Nanomedicine 1 2006 229 239
107. M.J. Hawkins, P. Soon-Shiong, and N. Desai Protein nanoparticles as drug carriers in clinical medicine Adv Drug Deliv Rev 60 2008 876 885
108. S.A. Cannistra Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough? J Clin Oncol 28 2010 3101 3103
109. M.E. Perez-Lopez, T. Curiel, J.G. Gomez, and M. Jorge Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer Anticancer Drugs 18 2007 611 617 (Pubitemid 46597416)
110. M.G. Teneriello, P.C. Tseng, M. Crozier, C. Encarnacion, K. Hancock, and M.J. Messing Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer J Clin Oncol 27 2009 1426 1431
111. S. Ramachandran, A.P. Quist, S. Kumar, and R. Lal Cisplatin nanoliposomes for cancer therapy: AFM and fluorescence imaging of cisplatin encapsulation, stability, cellular uptake, and toxicity Langmuir 22 2006 8156 8162 (Pubitemid 44418913)
112. M.K. Lee, S.J. Lim, and C.K. Kim Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles Biomaterials 28 2007 2137 2146
113. R.W. Staffhorst, K. van der Born, C.A. Erkelens, I.H. Hamelers, G.J. Peters, and E. Boven Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts Anticancer Drugs 19 2008 721 727
114. Chang R.S., Kim J., Lee H.Y., Han S.E., Na J., and Kim K. Reduced dose-limiting toxicity of intraperitoneal mitoxantrone chemotherapy using cardiolipin-based anionic liposomes Nanomedicine 2010 Published online.
115. P. Xu, E.A. Van Kirk, W.J. Murdoch, Y. Zhan, D.D. Isaak, and M. Radosz Anticancer efficacies of cisplatin-releasing pH-responsive nanoparticles Biomacromolecules 7 2006 829 835
116. H. Devalapally, D. Shenoy, S. Little, R. Langer, and M. Amiji Poly (ethylene oxide)-modified poly (beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model Cancer Chemother Pharmacol 59 2007 477 484 (Pubitemid 46122326)
117. J.O. Kim, A.V. Kabanov, and T.K. Bronich Polymer micelles with cross-linked polyanion core for delivery of a cationic drug doxorubicin J Control Release 138 2009 197 204
118. Y. Wang, D. Xin, K. Liu, M. Zhu, and J. Xiang Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity Bioconjug Chem 20 2009 2214 2221
119. Y. Shen, E. Jin, B. Zhang, C.J. Murphy, M. Sui, and J. Zhao Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery J Am Chem Soc 132 2010 4259 4265
120. Z. Feng, G. Zhao, L. Yu, D. Gough, and S.B. Howell Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane Cancer Chemother Pharmacol 65 2010 923 930
121. S. Aryal, C.M. Hu, and L. Zhang Polymer-cisplatin conjugate nanoparticles for acid-responsive drug delivery ACS Nano 4 2010 251 258
122. Y. Liu, L. Huang, and F. Liu Paclitaxel nanocrystals for overcoming multidrug resistance in cancer Mol Pharm 7 2010 665 667
123. 4 nanoparticles loaded with cisplatin on SKOV3/DDP ovarian carcinoma cells Int J Nanomedicine 4 2009 107 114
124. S. Cafaggi, E. Russo, R. Stefani, R. Leardi, G. Caviglioli, and B. Parodi Preparation and evaluation of nanoparticles made of chitosan or N-trimethyl chitosan and a cisplatin-alginate complex J Control Release 121 2007 110 123 (Pubitemid 47161043)
125. H. Lu, B. Li, Y. Kang, W. Jiang, Q. Huang, and Q. Chen Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting Cancer Chemother Pharmacol 59 2007 175 181 (Pubitemid 44885147)
126. J.J. Khandare, S. Jayant, A. Singh, P. Chandna, Y. Wang, and N. Vorsa Dendrimer versus linear conjugate: influence of polymeric architecture on the delivery and anticancer effect of paclitaxel Bioconjug Chem 17 2006 1464 1472 (Pubitemid 44851491)
127. J. Luo, K. Xiao, Y. Li, J.S. Lee, L. Shi, and Y.H. Tan Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment Bioconjug Chem 21 2010 1216 1224
128. S. Zhu, M. Hong, L. Zhang, G. Tang, Y. Jiang, and Y. Pei PEGylated PAMAM dendrimer-doxorubicin conjugates: in vitro evaluation and in vivo tumor accumulation Pharm Res 27 2010 161 174
129. M.P. Ponnusamy, G. Venkatraman, A.P. Singh, S.C. Chauhan, S.L. Johansson, and M. Jain Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis Cancer Lett 251 2007 247 257 (Pubitemid 46669795)
130. X. Zhao, H. Li, and R.J. Lee Targeted drug delivery via folate receptors Expert Opin Drug Deliv 5 2008 309 319 (Pubitemid 351454380)
131. P. Mukherjee, R. Bhattacharya, P. Wang, L. Wang, S. Basu, and J.A. Nagy Antiangiogenic properties of gold nanoparticles Clin Cancer Res 11 2005 3530 3534 (Pubitemid 40627908)
132. G. Sahay, D.Y. Alakhova, and A.V. Kabanov Endocytosis of nanomedicines J Control Release 145 2010 182 195
133. C.R. Patra, R. Bhattacharya, and P. Mukherjee Fabrication and functional characterization of goldnanoconjugates for potential application in ovarian cancer J Mater Chem 20 2010 547 554
134. R. Bhattacharya, C.R. Patra, A. Earl, S. Wang, A. Katarya, and L. Lu Attaching folic acid on gold nanoparticles using noncovalent interaction via different polyethylene glycol backbones and targeting of cancer cells Nanomed Nanotechnol Biol Med 3 2007 224 238 (Pubitemid 47332348)
135. K. Hasegawa, T. Nakamura, M. Harvey, Y. Ikeda, A. Oberg, and M. Figini The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer Clin Cancer Res 12 2006 6170
136. Y. Ren, S.M. Wong, and L.Y. Lim Folic acid-conjugated protein cages of a plant virus: a novel delivery platform for doxorubicin Bioconjug Chem 18 2007 836 843 (Pubitemid 47010805)
137. L. Zhang, S. Hou, S. Mao, D. Wei, X. Song, and Y. Lu Uptake of folate-conjugated albumin nanoparticles to the SKOV3 cells Int J Pharm 287 2004 155 162 (Pubitemid 39487253)
138. D. Kim, Z.G. Gao, E.S. Lee, and Y.H. Bae In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer Mol Pharm 6 2009 1353 1362
139. S.M. Lee, H. Chen, T.V. O'Halloran, and S.B.T. Nguyen "Clickable" polymer-caged nanobins as a modular drug delivery platform J Am Chem Soc 131 2009 9311 9320
140. R. Zeineldin, M. Al-Haik, and L.G. Hudson Role of polyethylene glycol integrity in specific receptor targeting of carbon nanotubes to cancer cells Nano Lett 9 2009 751 757
141. K.E. Scarberry, E.B. Dickerson, J.F. McDonald, and Z.J. Zhang Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells J Am Chem Soc 130 2008 10258 10262
142. K.E. Scarberry, E.B. Dickerson, Z.J. Zhang, B.B. Benigno, and J.F. McDonald Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles Nanomedicine 6 2010 399 408
143. C. Xu, Z. Yuan, N. Kohler, J. Kim, M.A. Chung, and S. Sun FePt nanoparticles as an Fe reservoir for controlled Fe release and tumor inhibition J Am Chem Soc 131 2009 15346 15351
144. X.Y. Zhang, J. Chen, Y.F. Zheng, X.L. Gao, Y. Kang, and J.C. Liu Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo Cancer Res 69 2009 6506 6514
145. A. Cirstoiu-Hapca, F. Buchegger, N. Lange, L. Bossy, R. Gurny, and F. Delie Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: therapeutic efficacy and biodistribution in mice J Control Release 144 2010 324 331
146. W.W. Wang, D. Das, S.A. McQuarrie, and M.R. Suresh Design of a bifunctional fusion protein for ovarian cancer drug delivery: single-chain anti-CA125 core-streptavidin fusion protein Eur J Pharm Biopharm 65 2007 398 405
147. M.M. Yallapu, D.M. Maher, V. Sundram, M.C. Bell, M. Jaggi, and S.C. Chauhan Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth J Ovarian Res 3 2010 11
148. J.A. Coulter, H.O. McCarthy, J. Xiang, W. Roedl, E. Wagner, and T. Robson Nitric oxide - a novel therapeutic for cancer Nitric Oxide 19 2008 192 198
149. D. Hirst, and T. Robson Targeting nitric oxide for cancer therapy J Pharm Pharmacol 59 2007 3 13 (Pubitemid 46133038)
150. J.E. Saavedra, A. Srinivasan, G.S. Buzard, K.M. Davies, D.J. Waterhouse, and K. Inami PABA/NO as an anticancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity J Med Chem 49 2006 1157 1164 (Pubitemid 43221662)
151. A. Bratasz, N.M. Weir, N.L. Parinandi, J.L. Zweier, R. Sridhar, and L.J. Ignarro Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin Proc Natl Acad Sci USA 103 2006 3914 3919 (Pubitemid 43376655)
152. T. Kaur, R.A. Slavcev, and S.D. Wettig Addressing the challenge: current and future directions in ovarian cancer therapy Curr Gene Ther 9 2009 434 458
153. Y.H. Huang, G.T. Zugates, W. Peng, D. Holtz, C. Dunton, and J.J. Green Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice Cancer Res 69 2009 6184 6191
154. Y.K. Oh, and T.G. Park siRNA delivery systems for cancer treatment Adv Drug Deliv Rev 61 2009 850 862
155. S. Akhtar, and I.F. Benter Nonviral delivery of synthetic siRNAs in vivo J Clin Invest 117 2007 3623 3632 (Pubitemid 350224068)
156. L. Sepp-Lorenzino, and M. Ruddy Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides Clin Pharmacol Ther 84 2008 628 632
157. S. Spagnou, A.D. Miller, and M. Keller Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA Biochemistry 43 2004 13348 13356 (Pubitemid 39391135)
158. Y. Higuchi, S. Kawakami, and M. Hashida Strategies for in vivo delivery of siRNAs: recent progress BioDrugs 24 2010 195 205
159. http://www.calandopharma.com/technology/rondel/in-the-clinic/
160. W. Chen, R. Bardhan, M. Bartels, C. Perez-Torres, R.G. Pautler, and N.J. Halas A molecularly targeted theranostic probe for ovarian cancer Mol Cancer Ther 9 2010 1028 1038
161. E.V. Stevens, A.W. Carpenter, J.H. Shin, J. Liu, C.J. Der, and M.H. Schoenfisch Nitric oxide-releasing silica nanoparticle inhibition of ovarian cancer cell growth Mol Pharm 7 2010 1231 1242
162. Y.H. Huang, G.T. Zugates, W. Peng, D. Holtz, C. Dunton, and J.J. Green Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice Cancer Res 69 2009 6184
163. H.K. de Wolf, J. Luten, C.J. Snel, G. Storm, and W.E. Hennink Biodegradable, cationic methacrylamide-based polymers for gene delivery to ovarian cancer cells in mice Mol Pharm 5 2008 349 357 (Pubitemid 351579137)
164. V.A. Sethuraman, K. Na, and Y.H. Bae pH-responsive sulfonamide/PEI system for tumor specific gene delivery: an in vitro study Biomacromolecules 7 2006 64 70 (Pubitemid 43154479)
165. Y. Wang, M. Saad, R.I. Pakunlu, J.J. Khandare, O.B. Garbuzenko, and A.A. Vetcher Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 enhances the efficacy of chemotherapy in drug-resistant tumor Clin Cancer Res 14 2008 3607
166. H.D. Han, L.S. Mangala, J.W. Lee, M.M.K. Shahzad, H.S. Kim, and D.Y. Shen Targeted gene silencing using RGD-labeled chitosan nanoparticles Clin Cancer Res 16 2010 3910 3922
167. S. Kirkland-York, Y. Zhang, A.E. Smith, A.W. York, F. Huang, and C.L. McCormick Tailored design of Au nanoparticle-siRNA carriers utilizing reversible addition-fragmentation chain transfer polymers Biomacromolecules 11 2010 1052 1059
168. M.L. Patil, M. Zhang, S. Betigeri, O. Taratula, H. He, and T. Minko Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery Bioconjug Chem 19 2008 1396 1403 (Pubitemid 352032339)
169. W.H. Blackburn, E.B. Dickerson, M.H. Smith, J.F. McDonald, and L.A. Lyon Peptide-functionalized nanogels for targeted siRNA delivery Bioconjug Chem 20 2009 960 968
170. T. Tanaka, L.S. Mangala, P.E. Vivas-Mejia, R. Nieves-Alicea, A.P. Mann, and E. Mora Sustained small interfering RNA delivery by mesoporous silicon particles Cancer Res 70 2010 3687
171. C.N. Landen, W.M. Merritt, L.S. Mangala, A.M. Sanguino, C. Bucana, and C. Lu Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer Cancer Biol Ther 5 2006 1708 1713
172. Yallapu M.M., Gupta B.K., Jaggi M., and Chauhan S.C. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells J Colloid Interface Sci 2010
173. M.M. Yallapu, M. Jaggi, and S.C. Chauhan Scope of nanotechnology in ovarian cancer therapeutics J Ovarian Res 3 2010 19
174. L.A. Nagahara, J.S. Lee, L.K. Molnar, N.J. Panaro, D. Farrell, and K. Ptak Strategic workshops on cancer nanotechnology Cancer Res 70 2010 4265 4268
175. R.J. Zemp Nanomedicine: detecting rare cancer cells Nat Nanotechnol 4 2009 798 799
176. P.P. Szotek, R. Pieretti-Vanmarcke, P.T. Masiakos, D.M. Dinulescu, D. Connolly, and R. Foster Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness Proc Natl Acad Sci USA 103 2006 11154 11159 (Pubitemid 44156488)
177. G. Ferrandina, G. Bonanno, L. Pierelli, A. Perillo, A. Procoli, and A. Mariotti Expression of CD133-1 and CD133-2 in ovarian cancer Int J Gynecol Cancer 18 2008 506 514 (Pubitemid 351668323)
178. Q. Gao, L. Geng, G. Kvalheim, G. Gaudernack, and Z. Suo Identification of cancer stem-like side population cells in ovarian cancer cell line OVCAR-3 Ultrastruct Pathol 33 2009 175 181
179. T. Baba, P.A. Convery, N. Matsumura, R.S. Whitaker, E. Kondoh, and T. Perry Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells Oncogene 28 2009 209 218
180. A.B. Alvero, R. Chen, H.H. Fu, M. Montagna, P.E. Schwartz, and T. Rutherford Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance Cell Cycle 8 2009 158 166
181. A.P. Kusumbe, A.M. Mali, and S.A. Bapat CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature Stem Cells 27 2009 498 508
182. S.A. Bapat, A.M. Mali, C.B. Koppikar, and N.K. Kurrey Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer Cancer Res 65 2005 3025 3029 (Pubitemid 40524578)
183. N.B. Berry, and S.A. Bapat Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype J Ovarian Res 1 2008 8
184. S.K. Murphy Targeting ovarian cancer-initiating cells Anticancer Agents Med Chem 10 2010 157 163
185. B.L. Allen, P.D. Kichambare, P. Gou, I.I. Vlasova, A.A. Kapralov, and N. Konduru Biodegradation of single-walled carbon nanotubes through enzymatic catalysis Nano Lett 8 2008 3899 3903
186. Allen B.L., Kotchey G.P., Chen Y., Yanamala N.V., Klein-Seetharaman J., and Kagan V.E. Mechanistic investigations of horseradish peroxidase-catalyzed degradation of single-walled carbon nanotubes J Am Chem Soc 2009
187. A. Verma, and F. Stellacci Effect of surface properties on nanoparticle-cell interactions Small 6 2010 12 21
188. M.D. Chavanpatil, A. Khdair, and J. Panyam Nanoparticles for cellular drug delivery: mechanisms and factors influencing delivery J Nanosci Nanotechnol 6 2006 2651 2663 (Pubitemid 44579937)
189. V.J. Mohanraj, and Y. Chen Nanoparticles - a review Trop J Pharm Res 5 2006 561 573
190. Thomas D.G., Pappu R.V., and Baker N.A. NanoParticle Ontology for cancer nanotechnology research J Biomed Inform 2010 Published online.